Deep Vein Thrombosis – Pipeline Review, 2019

Deep vein thrombosis (DVT) is defined as a medical condition where a blood clot is formed within the deep veins of the thighs, lower legs, arms or pelvis. The blood circulation is blocked within the veins leading to swelling, severe pain, and appearance of bluish color around the affected area. thromboembolism, post-thrombotic syndrome, and postphlebitic syndrome are some of the other names associated with deep vein thrombosis. A blood clot can occur due to several factors such as reduced activity or mobility, blood vessel damage due to surgery, and reduced estrogen level due to the use of birth control pills undergoing hormonal replacement therapy. Additionally, obesity, various heart, and respiratory disease are also some of the risk factors associated with deep vein thrombosis.

According to the Centers for Disease Control and Prevention (CDC), around 900,000 people in united states are affected by deep vein thrombosis every year and 10% to 30% of people die within one month of diagnosis. Currently, anticoagulants are standard therapy used for the treatment of deep vein thrombosis. Heparin, warfarin, and enoxaparin are some of the blood thinners medications used for the treatment of deep vein thrombosis. Inferior vena cava (IVC) filters can be used as an alternative treatment option. surgical thrombectomy is usually preferred when the size of a blood clot increases or caused damages to the veins.

Various government funded organizations along with pharmaceutical companies have been focusing on studying and developing new treatment options for deep vein thrombosis. For instance; Edoxaban low dose, which is being studied by DAIICHI SANKYO COMPANY, LIMITED, is currently in phase-1 clinical trials for the study of the first evaluation of a single dose of edoxaban in pediatric subjects who require anticoagulant therapy to see pharmacokinetic and pharmacodynamics, and to compare if these effects are similar to those observed in adults.

At present around 66% of the pipeline candidates for deep vein thrombosis are in the phase-3 and phase-4 stage. More than half of the studies are sponsored by government funded research institutes.

Report Description

The report on ‘Deep Vein Thrombosis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for deep vein thrombosis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for deep vein thrombosis.

The report on ‘Deep Vein Thrombosis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products fordeep vein thrombosis


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Deep vein thrombosis


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary